Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical First-in-human Dose Escalation Study Evaluating the Safety and Tolerability of Intranodal Administration of an RNA-based Cancer Vaccine Targeting Two Tumor-associated Antigens in Patients With Advanced Melanoma

NCT01684241 is registered in ClinicalTrials.gov with BioNTech RNA Pharmaceuticals GmbH as lead sponsor.

NCT NCT01684241
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01684241 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical First-in-human Dose Escalation Study Evaluating the Safety and Tolerability of Intranodal Administration of an RNA-based Cancer Vaccine Targeting Two Tumor-associated Antigens in Patients With Advanced Melanoma
Lead sponsor
BioNTech RNA Pharmaceuticals GmbH
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2012
Completion date
July 31, 2015
Enrollment
29 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma